Cytotoxic effect of a lipophilic alkylating agent after incorporation into low density lipoprotein or emulsions: Studies in human leukemic cells

Leukemia Research

Volumn 30, Issue 2, 2006, Pages 136-144

  Masquelier, Michèle ^a   Lundberg, Bo ^b   Peterson, Curt ^c   Vitols, Sigurd ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ÅBO AKADEMI UNIVERSITY   (Finland)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Acute myeloid leukemia; DNR; LDL; Lipid emulsion; Melphalan

Indexed keywords

ALKYLATING AGENT; DAUNORUBICIN; DRUG CARRIER; LIPID EMULSION; LIPOSOME; LOW DENSITY LIPOPROTEIN; MELPHALAN; UNCLASSIFIED DRUG; VALRUBICIN; WB 4291;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL STRAIN HL 60; CELL STRAIN K 562; CONTROLLED STUDY; CYTOTOXICITY; EMULSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; LIPID TRANSPORT; LIPOPHILICITY; MICROEMULSION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, ALKYLATING; DRUG CARRIERS; DRUG STABILITY; EMULSIONS; HL-60 CELLS; HUMANS; K562 CELLS; LEUKEMIA; LIPOPROTEINS, LDL; MELPHALAN; NITROGEN MUSTARD COMPOUNDS; OLEIC ACID;

EID: 28844499195     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.06.012     Document Type: Article

References (24)

1. C. de Duve, T. de Barsy, B. Poole, A. Trouet, P. Tulkens, and F. Van Hoof Commentary. Lysosomotropic agents Biochem Pharmacol 23 1974 2495 2531
2. C. de Duve, A. Trouet, D.D. Campeneere, and R. Baurian Liposomes as lysosomotropic carriers Ann N Y Acad Sci 308 1978 226 234
3. Y.K. Ho, R.G. Smith, M.S. Brown, and J.L. Goldstein Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells Blood 52 1978 1099 1114
4. D. Gal, P.C. MacDonald, J.C. Porter, and E.R. Simpson Cholesterol metabolism in cancer cells in monolayer culture. VI. Metabolism of high-density lipoprotein Arch Biochem Biophys 214 1982 726 733
5. S. Vitols, G. Gahrton, A. Ost, and C. Peterson Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation Blood 63 1984 1186 1193
6. S. Vitols, K. Soderberg-Reid, M. Masquelier, B. Sjostrom, and C. Peterson Low density lipoprotein for delivery of a water-insoluble alkylating agent to malignant cells. In vitro and in vivo studies of a drug-lipoprotein complex Br J Cancer 62 1990 724 729
7. B.L. Samuels, and J.D. Bitran High-dose intravenous melphalan: a review J Clin Oncol 13 1995 1786 1799
8. J.L. Goldstein, and M.S. Brown The low-density lipoprotein pathway and its relation to atherosclerosis Annu Rev Biochem 46 1977 897 930
9. A.M. Sakashita, S.P. Bydlowski, D.A. Chamone, and R.C. Maranhao Plasma kinetics of an artificial emulsion resembling chylomicrons in patients with chronic lymphocytic leukemia Ann Hematol 79 2000 687 690
10. B. Lundberg Preparation of drug-carrier emulsions stabilized with phosphatidylcholine-surfactant mixtures J Pharm Sci 83 1994 72 75
11. L. Tatidis, M. Masquelier, and S. Vitols Elevated uptake of low density lipoprotein by drug resistant human leukemic cell lines Biochem Pharmacol 63 2002 2169 2180
12. M. Masquelier, Q.F. Zhou, A. Gruber, and S. Vitols Relationship between daunorubicin concentration and apoptosis induction in leukemic cells Biochem Pharmacol 67 2004 1047 1056
13. R.J. Havel, H.A. Eder, and J.H. Bragdon The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum J Clin Invest 34 1955 1345 1353
14. M. Masquelier, S. Vitols, and C. Peterson Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice Cancer Res 46 1986 3842 3847
15. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J Immunol Methods 65 1983 55 63
16. C. Paul, B. Lonnqvist, G. Gahrton, D. Lockner, and C. Peterson Reducing the cardiotoxicity of anthracyclines by complex-binding to DNA: report of three cases Cancer 48 1981 1531 1534
17. C. Paul, M. Bjorkholm, I. Christenson, L. Engstedt, G. Gahrton, and R. Hast Comparison of daunorubicin and daunorubicin-DNA complex in the treatment of acute nonlymphoblastic leukemia Cancer Chemother Pharmacol 6 1981 65 73
18. C. Schroder, K. Eckert, and H.R. Maurer Tributyrin induces growth inhibitory and differentiating effects on HT-29 colon cancer cells in vitro Int J Oncol 13 1998 1335 1340
19. J.M. Dintaman, and J.A. Silverman Inhibition of p-glycoprotein by d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS) Pharm Res 16 1999 1550 1556
20. R. Zhou, Y. Wang, A. Gruber, R. Larsson, E. Castanos-Velez, and E. Liliemark Topoisomerase II-mediated alterations of K562 drug resistant sublines Med Oncol 16 1999 191 198
21. A.G. Bosanquet Stability of melphalan solutions during preparation and storage J Pharm Sci 74 1985 348 351
22. N.J. Vogelzang Continuous infusion chemotherapy: a critical review J Clin Oncol 2 1984 1289 1304
23. F. Pinguet, S. Culine, F. Bressolle, C. Astre, M.P. Serre, and C. Chevillard A phase I and pharmacokinetic study of melphalan using a 24-h continuous infusion in patients with advanced malignancies Clin Cancer Res 6 2000 57 63
24. A.G. Bosanquet, and M.C. Bird Degradation of melphalan in vitro: rationale for the use of continuous exposure in chemosensitivity assays Cancer Chemother Pharmacol 21 1988 211 215